trial · primary record
Rilvegostomig
Advanced or Metastatic Non-small Cell Lung Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 152 |
| Primary completion | 2029-02-23 |
| Primary endpoint | Part A and Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs) |
| Registry ID | NCT06996782 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:28.892Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06996782
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Rilvegostomig · compound